5 Results for "

epileptogenesis

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "epileptogenesis" in MCE Product Catalog:

Cat. No.: HY-121872
CAS No.: 222315-88-0
Purity:  ≥95.0%
Research Areas:  

Neurological Disease

DP-b99 is a blood-brain barrier-permeable inhibitor of CYP2C9 and MMP-9, with a Ki value of 4.655 μM against CYP2C9. DP-b99 inhibits CYP2C9 via apparent non-competitive inhibition, mainly chelates pathological Zn 2+ in the membrane environment, attenuates the elevation of intracellular Zn 2+ and Ca 2+ levels, delays seizure onset and reduces seizure severity, and also prevents MMP-9-dependent dendritic spine remodeling, β-dystroglycan cleavage and gelatinase activity. DP-b99 can be used in the research of acute ischemic stroke, epileptogenesis and stroke .
loading...
    loading...
Cat. No.: HY-155811
CAS No.: 2377187-09-0
Purity:  99.85%
Target:  

iGluR

Research Areas:  

Neurological Disease

DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .
loading...
    loading...
Cat. No.: HY-116143
CAS No.: 1352011-38-1
Target:  

MAGL

Research Areas:  

Metabolic Disease

SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .
loading...
    loading...
Cat. No.: HY-179142
CAS No.: 3073624-74-2
COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .
loading...
    loading...
Cat. No.: HY-100815E
CAS No.: 2922283-04-1
Synonyms: (±)-AMPA hydrochloride
Target:  

iGluR

Research Areas:  

Neurological Disease

(RS)-AMPA hydrochloride ((±)-AMPA hydrochloride) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrochloride hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .
loading...
    loading...